Review for "A look to the future in non‐alcoholic fatty liver disease: Are GLP ‐1 analogues or SGLT ‐2 inhibitors the answer?"

Mapping Intimacies ◽

10.1111/dom.14196/v2/review1 ◽

2020 ◽

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Alcoholic Fatty Liver ◽

Alcoholic Fatty Liver Disease

Download Full-text

Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future

World Journal of Hepatology ◽

10.4254/wjh.v7.i25.2597 ◽

2015 ◽

Vol 7 (25) ◽

pp. 2597 ◽

Author(s):

Mehran Rahimlou

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Dietary Supplements ◽

Fatty Liver Disease ◽

Alcoholic Fatty Liver ◽

Alcoholic Fatty Liver Disease ◽

Disease Present

Download Full-text

Review for "A look to the future in non‐alcoholic fatty liver disease: Are GLP ‐1 analogues or SGLT ‐2 inhibitors the answer?"

10.1111/dom.14196/v3/review1 ◽

2020 ◽

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Alcoholic Fatty Liver ◽

Alcoholic Fatty Liver Disease

Download Full-text

Review for "A look to the future in non‐alcoholic fatty liver disease: Are GLP ‐1 analogues or SGLT ‐2 inhibitors the answer?"

10.1111/dom.14196/v1/review2 ◽

2020 ◽

Author(s):

Qing Li

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Alcoholic Fatty Liver ◽

Alcoholic Fatty Liver Disease

Download Full-text

Non-alcoholic fatty liver disease pathogenesis: The present and the future

Digestive and Liver Disease ◽

10.1016/j.dld.2009.01.004 ◽

2009 ◽

Vol 41 (9) ◽

pp. 615-625 ◽

Author(s):

S. Petta ◽

C. Muratore ◽

A. Craxì

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Disease Pathogenesis ◽

Alcoholic Fatty Liver ◽

Alcoholic Fatty Liver Disease

Download Full-text

Author response for "A look to the future in non‐alcoholic fatty liver disease: Are GLP ‐1 analogues or SGLT ‐2 inhibitors the answer?"

10.1111/dom.14196/v3/response1 ◽

2020 ◽

Author(s):

Rebecca K Vincent ◽

David M Williams ◽

Marc Evans

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Author Response ◽

Alcoholic Fatty Liver ◽

Alcoholic Fatty Liver Disease

Download Full-text

Decision letter for "A look to the future in non‐alcoholic fatty liver disease: Are GLP ‐1 analogues or SGLT ‐2 inhibitors the answer?"

10.1111/dom.14196/v3/decision1 ◽

2020 ◽

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Alcoholic Fatty Liver ◽

Alcoholic Fatty Liver Disease

Download Full-text

Review for "A look to the future in non‐alcoholic fatty liver disease: Are GLP ‐1 analogues or SGLT ‐2 inhibitors the answer?"

10.1111/dom.14196/v1/review1 ◽

2020 ◽

Author(s):

luciana pechmann

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Alcoholic Fatty Liver ◽

Alcoholic Fatty Liver Disease

Download Full-text

Decision letter for "A look to the future in non‐alcoholic fatty liver disease: Are GLP ‐1 analogues or SGLT ‐2 inhibitors the answer?"

10.1111/dom.14196/v1/decision1 ◽

2020 ◽

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Alcoholic Fatty Liver ◽

Alcoholic Fatty Liver Disease

Download Full-text

Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future

World Journal of Gastroenterology ◽

10.3748/wjg.v20.i31.10851 ◽

2014 ◽

Vol 20 (31) ◽

pp. 10851 ◽

Author(s):

Emer Fitzpatrick

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Current Status ◽

Alcoholic Fatty Liver ◽

Noninvasive Biomarkers ◽

Alcoholic Fatty Liver Disease

Download Full-text

Decision letter for "A look to the future in non‐alcoholic fatty liver disease: Are GLP ‐1 analogues or SGLT ‐2 inhibitors the answer?"

10.1111/dom.14196/v2/decision1 ◽

2020 ◽

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Alcoholic Fatty Liver ◽

Alcoholic Fatty Liver Disease

Download Full-text